Jan 22 (Reuters) - Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Junoâ€™s pipeline of CAR-T cancer drugs.
Celgene already owns 9.7 percent in Juno and will offer $87 per share.
Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur
 